Limited access to CD4 tests misses late diagnoses and advanced HIV disease (AHD)
8 August 2025. Related: Conference reports, Treatment strategies, Guidelines, Coinfections and complications.
Conference reports
Induced stress can increase HIV dynamics
7 August 2025. Related: Conference reports, Cure-related research, Basic science and immunology.
Featured IAS 2025: WHO major updates on injectables, AHD, breastfeeding, infant prophylaxis and peer support
2 August 2025. Related: Conference reports, Guidelines.
13th IAS Conference on HIV Science (IAS 2025): Introduction and early reports
31 July 2025. Related: Conference reports, Activism & advocacy.
IAS 2025: The Kigali Manifesto on the inclusion of people living with HIV in clinical research
31 July 2025. Related: Conference reports, Treatment access, Coinfections and complications, Cancer and HIV, Activism & advocacy, Research studies.
IAS 2025: Switching to injectable CAB/RPV-LA with detectable viral load: results from the OPERA cohort
28 July 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
IAS 2025: Switching to dual ART after durable suppression on triple-drug ART in West and Central Africa
27 July 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
IAS 2025: Increases in reports of HIV criminalisation cases globally
26 July 2025. Related: Conference reports, Activism & advocacy.
IAS 2025: Once-weekly oral ART with ulonivirine plus islatravir: 24-week phase 2 results
20 July 2025. Related: Conference reports, Antiretrovirals.
IAS 2025: Reduced dosing could be a safe option for adults: crisis response to ART stock-outs
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: 5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no differences in clinical outcomes
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks
17 July 2025. Related: Conference reports, Antiretrovirals, Drug resistance.
IAS 2025: Once-monthly oral PrEP using MK-8527: the drug that will stop HIV
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: “We will not be erased” – a community Call to Action
15 July 2025. Related: Conference reports, Treatment access, Activism & advocacy.
IAS 2025: HIV care is political: early focus on the funding crisis
12 July 2025. Related: Conference reports, Treatment access.
IAS 2025: HIV cure research at IAS 2025
12 July 2025. Related: Conference reports.
IAS 2025: Kigali Call to Action: sign-on to global leaders
1 July 2025. Related: Conference reports.
The RIO study: Q&A about controlling HIV with bNAbs
21 April 2025. Related: Conference reports, Cure-related research.
CROI 2025: Webcasts and other resources now open access
16 April 2025. Related: Conference reports.
Continued reports from CROI 2025
13 April 2025. Related: Conference reports.
CROI 2025: LAPTOP, EC rebounds after 32 years, two more HSCT cures
12 April 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
CROI 2025: Rebecca Denison gives opening community talk on 40 years of HIV
7 April 2025. Related: Conference reports, Activism & advocacy.
CROI 2025: BHIVA best of CROI feedback now online
1 April 2025. Related: Conference reports, On the web.
CROI 2025: Two bNAbs enable viral suppression off-ART in African women in the FRESH cohort
1 April 2025. Related: Conference reports, Cure-related research.
CROI 2025: Introduction to this year’s conference
22 March 2025. Related: Conference reports.
CROI 2025: RIO study: Dual-bNABs keep viral load undetectable off-ART – plus a potential first case of vaccine-like HIV remission
21 March 2025. Related: Conference reports, Cure-related research.
CROI 2025: Switching to daily fixed-dose doravirine/islatravir: two randomised phase 3 studies
20 March 2025. Related: Conference reports, Antiretrovirals.
CROI 2025: Tecovirimat has no benefit against mpox in STOMP study
18 March 2025. Related: Conference reports, mpox.
CROI 2025: Ensitrelvir significantly reduces risk of developing COVID-19 after household exposure
18 March 2025. Related: Conference reports, COVID-19.
CROI 2025: N6LS: 4-monthly injectable bNAb with monthly injectable cabotegravir
18 March 2025. Related: Conference reports, Antiretrovirals.
CROI 2025: Reducing Biktarvy from daily to only once, twice or three times a week
17 March 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
CROI 2025: Potential for once-yearly lenacapavir injections
16 March 2025. Related: Conference reports, Antiretrovirals, PK and drug interactions, HIV prevention and transmission.
CROI 2025: Delegates send open letter to protest US cuts
12 March 2025. Related: Conference reports, Activism & advocacy.
CROI 2025: Stand Up For Science rally against Trump funding freeze
9 March 2025. Related: Conference reports, Activism & advocacy.
ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir
1 January 2025. Related: Special reports, Conference reports, Pipeline report, Antiretrovirals.
HIVR4P 2024 conference resources now open access
12 December 2024. Related: Conference reports, On the web.
Glasgow HIV Congress 2024: Introduction and links
26 November 2024. Related: Conference reports.
Once-weekly oral ART with islatravir plus lenacapavir sustains results to week 48
26 November 2024. Related: Conference reports, Antiretrovirals.
EACS guidelines: New format and contents includes chemsex
26 November 2024. Related: Conference reports, Guidelines.
Double dose start for oral PrEP in new EACS guidelines – rapid protection in two hours
26 November 2024. Related: Conference reports, Guidelines, HIV prevention and transmission.
Future PrEP and new results on lenacapavir from PURPOSE 1 and 2 – does HIV exposure explain incident cases?
26 November 2024. Related: Conference reports, HIV prevention and transmission.
Liverpool University Drug Interaction website recognised for global impact on research and care
26 November 2024. Related: Conference reports, PK and drug interactions, Activism & advocacy.
HCV coinfection approaches zero in Spain: but cirrhosis and reinfection among gay men are still significant even with high rates of cure
26 November 2024. Related: Conference reports, Hepatitis coinfection.
Dolutegravir/lamivudine vs triple ART have similar efficacy in advanced HIV infection with CD4 <200 and viral load >100,000
21 November 2024. Related: Conference reports, Antiretrovirals.
HIVR4P 2024: Introduction
14 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
Urgency of planning broad vaccine-like access to lenacapavir PrEP globally
13 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
Impact on CD4 counts of once-monthly islatravir in PrEP studies: early macaque results with MK-8527 follow-on compound
9 October 2024. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Lenacapavir PrEP in cisgender gay men, trans and gender-diverse people: results of the PURPOSE 2 study
9 October 2024. Related: Conference reports, HIV prevention and transmission.
HIVR4P 2024: Context of PrEP in Latin America
7 October 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
AIDS 2024: Including people living with HIV in non-HIV research
11 September 2024. Related: Conference reports, Treatment access, Cancer and HIV, Activism & advocacy.
IAS 2024: Open letter to IAS over online access
1 September 2024. Related: Editorial, Conference reports.
AIDS 2024: Ten early reports
12 August 2024. Related: Conference reports, Antiretrovirals.
Five days on two days off: Biktarvy in pilot FOTO study
12 August 2024. Related: Conference reports, Antiretrovirals.
Subcutaneous formulation of long-acting CAB/RPV discontinued
10 August 2024. Related: Conference reports, Antiretrovirals.
First data on third-generation integrase inhibitor from ViiV
10 August 2024. Related: Conference reports, Antiretrovirals.
Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study
10 August 2024. Related: Conference reports, Antiretrovirals.
AIDS 2024: Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more
29 July 2024. Related: Conference reports, HIV prevention and transmission.
Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV
26 July 2024. Related: Conference reports, Treatment access, HIV prevention and transmission.
AIDS 2024: Introduction to AIDS 2024
22 July 2024. Related: Conference reports.
UNAIDS report: The urgency of now – AIDS at a crossroads.
22 July 2024. Related: Conference reports, Activism & advocacy.
New community call to challenge social settings that drive HIV-related stigma
20 July 2024. Related: Conference reports, HIV prevention and transmission, Activism & advocacy.
HIV research to watch out for at the AIDS 2024 conference
18 July 2024. Related: Conference reports.
CROI 2024 final reports: statins, doxy-PEP and TAF implant
10 June 2024. Related: Conference reports, Coinfections and complications.
Doxy-PEP studies at CROI 2024
9 June 2024. Related: Conference reports, Coinfections and complications.
HIV and statins: REPRIEVE studies at CROI 2024
6 June 2024. Related: Conference reports, Weight, diabetes, metabolic complications.